It will be important to gain prospective data in randomized trials that study venetoclax with salvage chemotherapy or other targeted therapies (e.g., gilteritinib for FLT3-mutated r/r AML or ivosidenib/enasidenib in IDH1-/IDH2-mutated r/r AML). Here, IDH1 is linked to acute myeloid leukemia.